Excluding Viverso, ebitda fell 8 per cent in the latest year.
Nuplex didn't give explicit guidance for the 2013 year, saying earnings would benefit from its two-year NuLeap review of its businesses, full-year contribution from Viverso, new capacity in Vietnam and an estimated A$5 million contribution from Masterbatch in Australia.
The shares rose 1.9 per cent to $2.72, heading for the highest close in more than three months. The stock is rated a 'hold' based on five recommendations compiled by Reuters, with a price target of $2.50.
Reported profit beat the $59.6 million forecast of Forsyth Barr analyst John Cairns. Nuplex will pay a final dividend of 11 cents a share, unchanged from the previous year.
The NuLeap program $14 million in incremental benefits, beating the company's $10 million estimate.
"We has a strong second half as a result of improved unit margins in our global resin segment, the delivery of greater than expected NuLeap benefits and the first six months earnings contribution from Viverso," Severin said. "Combined these factors offset the impact of lower volumes in our global resin segment and the stronger New Zealand dollar."